From the Journals

Cardiovascular disease risk higher in patients with schizophrenia, metabolic syndrome


 

FROM THE MEDICAL JOURNAL OF THE ISLAMIC REPUBLIC OF IRAN

Metabolic syndrome is common among patients with schizophrenia, and those with metabolic syndrome are at significantly higher risk for cardiovascular disease, according to Shadi Naderyan Fe’li of the department of biostatistics and epidemiology at Shahid Sadoughi University of Medical Sciences in Yazd, Iran, and associates.

The cross-sectional study, performed on 100 patients with schizophrenia (83 men, 17 women), was published in the Medical Journal of the Islamic Republic of Iran. The overall prevalence of metabolic syndrome was 27% (men, 21.7%; women, 52.9%); the most common component of metabolic disorder was low HDL cholesterol in males and abdominal adiposity in females.

Based on Framingham Risk Scores, 76% of study participants had a low risk of cardiovascular disease, 16% had intermediate risk, and 8% had high risk. However, patients were almost twice as likely to have intermediate or high risk of cardiovascular disease if they also had metabolic syndrome (P = .042).

“Considering the findings of this study as well as other recent reports, psychiatrists and health care staff should be informed about the potential metabolic side effects of antipsychotics and unhealthy lifestyles among these patients. Furthermore, regular monitoring of metabolic risk factors is suggested. In addition, medical and behavioral interventions should be conducted for patients with [metabolic syndrome],” the investigators concluded.

The investigators reported that they had no conflicts of interest.

SOURCE: Fe’li SN et al. Med J Islam Repub Iran. 2019 Sep 16. doi: 10.34171/mjiri.33.97.

Recommended Reading

Sequential intercept model is really a ‘no-intercept model’
MDedge Psychiatry
Schizophrenia, bipolar disorder associated with increased risk of secondary TD
MDedge Psychiatry
FDA approves Caplyta to treat schizophrenia in adults
MDedge Psychiatry
Antipsychotics, dopamine, and pain
MDedge Psychiatry
Half of SLE patients have incident neuropsychiatric events
MDedge Psychiatry
Top research findings of 2018-2019 for clinical practice
MDedge Psychiatry
Lumateperone for schizophrenia
MDedge Psychiatry
Therapeutic drug monitoring of antipsychotics
MDedge Psychiatry
FDA strengthens warning regarding clozapine, serious bowel complication risk
MDedge Psychiatry
Understanding postpartum psychosis: From course to treatment
MDedge Psychiatry